-
1
-
-
0037954564
-
-
E. Garattini, R. Mendel, M.J. Romao, R. Wright, and M. Terao Biochem. J. 372 2008 15
-
(2008)
Biochem. J.
, vol.372
, pp. 15
-
-
Garattini, E.1
Mendel, R.2
Romao, M.J.3
Wright, R.4
Terao, M.5
-
2
-
-
78650379608
-
-
D.C. Pryde, D. Dalvie, Q. Hu, P. Jones, R.S. Obach, and T.-D. Tran J. Med. Chem. 53 2010 8441
-
(2010)
J. Med. Chem.
, vol.53
, pp. 8441
-
-
Pryde, D.C.1
Dalvie, D.2
Hu, Q.3
Jones, P.4
Obach, R.S.5
Tran, T.-D.6
-
4
-
-
78650303504
-
-
X. Zhang, H.-H. Liu, P. Weller, M. Zheng, W. Tao, J. Wang, G. Liao, M. Monshouwer, and G. Peltz Pharmacogenomics J. 11 2011 15
-
(2011)
Pharmacogenomics J.
, vol.11
, pp. 15
-
-
Zhang, X.1
Liu, H.-H.2
Weller, P.3
Zheng, M.4
Tao, W.5
Wang, J.6
Liao, G.7
Monshouwer, M.8
Peltz, G.9
-
5
-
-
72249086358
-
-
For recent examples, see
-
For recent examples, see: T.V. Magee, S.L. Ripp, B. Li, R.A. Buzon, and L. Chupak J. Med. Chem. 52 2009 7446
-
(2009)
J. Med. Chem.
, vol.52
, pp. 7446
-
-
Magee, T.V.1
Ripp, S.L.2
Li, B.3
Buzon, R.A.4
Chupak, L.5
-
6
-
-
80455173672
-
-
A. Linton, P. Kang, M. Ornelas, S. Kephart, Q. Hu, M. Pairish, Y. Jiang, and C. Guo J. Med. Chem. 54 2011 7705
-
(2011)
J. Med. Chem.
, vol.54
, pp. 7705
-
-
Linton, A.1
Kang, P.2
Ornelas, M.3
Kephart, S.4
Hu, Q.5
Pairish, M.6
Jiang, Y.7
Guo, C.8
-
7
-
-
79953280471
-
-
T.-D. Tran, D.C. Pryde, P. Jones, F.M. Adam, N. Benson, G. Bish, F. Calo, G. Ciaramella, R. Dixon, J. Duckworth, D.N.A. Fox, D.A. Hay, J. Hitchin, N. Horscroft, M. Howard, I. Gardner, H.M. Jones, C. Laxton, T. Parkinson, G. Parsons, K. Proctor, M.C. Smith, N. Smith, and A. Thomas Bioorg. Med. Chem. Lett. 21 2011 2389
-
(2011)
Bioorg. Med. Chem. Lett.
, vol.21
, pp. 2389
-
-
Tran, T.-D.1
Pryde, D.C.2
Jones, P.3
Adam, F.M.4
Benson, N.5
Bish, G.6
Calo, F.7
Ciaramella, G.8
Dixon, R.9
Duckworth, J.10
Fox, D.N.A.11
Hay, D.A.12
Hitchin, J.13
Horscroft, N.14
Howard, M.15
Gardner, I.16
Jones, H.M.17
Laxton, C.18
Parkinson, T.19
Parsons, G.20
Proctor, K.21
Smith, M.C.22
Smith, N.23
Thomas, A.24
more..
-
8
-
-
80052583341
-
-
P. Jones, D.C. Pryde, T.-D. Tran, F.M. Adam, G. Bish, F. Calo, G. Ciaramella, R. Dixon, J. Duckworth, D.N.A. Fox, D.A. Hay, J. Hitchin, N. Horscroft, M. Howard, C. Laxton, T. Parkinson, G. Parsons, K. Proctor, M.C. Smith, N. Smith, and A. Thomas Bioorg. Med. Chem. Lett. 21 2011 5939
-
(2011)
Bioorg. Med. Chem. Lett.
, vol.21
, pp. 5939
-
-
Jones, P.1
Pryde, D.C.2
Tran, T.-D.3
Adam, F.M.4
Bish, G.5
Calo, F.6
Ciaramella, G.7
Dixon, R.8
Duckworth, J.9
Fox, D.N.A.10
Hay, D.A.11
Hitchin, J.12
Horscroft, N.13
Howard, M.14
Laxton, C.15
Parkinson, T.16
Parsons, G.17
Proctor, K.18
Smith, M.C.19
Smith, N.20
Thomas, A.21
more..
-
11
-
-
79952528002
-
-
D.C. Pryde, T.-D. Tran, P. Jones, G.C. Parsons, G. Bish, F.M. Adam, M.C. Smith, D.S. Middleton, N. Smith, F. Calo, D. Hay, M. Paradowski, K.J.W. Proctor, T. Parkinson, C. Laxton, D.N.A. Fox, N.J. Horscroft, G. Ciaramella, H.M. Jones, J. Duckworth, N. Benson, A. Harrison, and R. Webster MedChemCommun 2 2011 185
-
(2011)
MedChemCommun
, vol.2
, pp. 185
-
-
Pryde, D.C.1
Tran, T.-D.2
Jones, P.3
Parsons, G.C.4
Bish, G.5
Adam, F.M.6
Smith, M.C.7
Middleton, D.S.8
Smith, N.9
Calo, F.10
Hay, D.11
Paradowski, M.12
Proctor, K.J.W.13
Parkinson, T.14
Laxton, C.15
Fox, D.N.A.16
Horscroft, N.J.17
Ciaramella, G.18
Jones, H.M.19
Duckworth, J.20
Benson, N.21
Harrison, A.22
Webster, R.23
more..
-
14
-
-
79960492508
-
-
F.M. Adam, G. Bish, F. Calo, C.L. Carr, N. Castro, D. Hay, P.B. Hodgson, P. Jones, C.J. Knight, M. Paradowski, G.C. Parsons, K.J.W. Proctor, D.C. Pryde, F. Rota, M.C. Smith, N. Smith, T.-D. Tran, J. Hitchin, and R. Dixon Org. Process Res. Dev. 15 2011 788
-
(2011)
Org. Process Res. Dev.
, vol.15
, pp. 788
-
-
Adam, F.M.1
Bish, G.2
Calo, F.3
Carr, C.L.4
Castro, N.5
Hay, D.6
Hodgson, P.B.7
Jones, P.8
Knight, C.J.9
Paradowski, M.10
Parsons, G.C.11
Proctor, K.J.W.12
Pryde, D.C.13
Rota, F.14
Smith, M.C.15
Smith, N.16
Tran, T.-D.17
Hitchin, J.18
Dixon, R.19
-
15
-
-
80054995309
-
-
D.A. Hay, F.A. Adam, G. Bish, F. Calo, R. Dixon, M.J. Fray, J. Hitchin, P. Jones, M. Paradowski, G.C. Parsons, K.J.W. Proctor, D.C. Pryde, N. Smith, and T.-D. Tran Tetrahedron Lett. 52 2011 5728
-
(2011)
Tetrahedron Lett.
, vol.52
, pp. 5728
-
-
Hay, D.A.1
Adam, F.A.2
Bish, G.3
Calo, F.4
Dixon, R.5
Fray, M.J.6
Hitchin, J.7
Jones, P.8
Paradowski, M.9
Parsons, G.C.10
Proctor, K.J.W.11
Pryde, D.C.12
Smith, N.13
Tran, T.-D.14
-
17
-
-
34547647483
-
-
2 humidified incubator. Ten microlitre of PBMC supernatant was added to HCV replicon cells prepared in Dulbecco's modified Eagle's medium containing 10% FCS plated in white-well tissue culture-grade 96-well plates (Perkin-Elmer) at 1 × 104 cells/well in a volume of 90 μl, and the cells were incubated for 48 h. Replicon levels were quantified using a Promega Bright Glo luciferase detection kit according to the manufacturer's instructions.
-
(2007)
Antimicrob. Agents Chemother.
, vol.51
, pp. 2969
-
-
Thomas, A.1
Laxton, C.2
Rodman, J.3
Myangar, N.4
Horscroft, N.J.5
Parkinson, T.6
-
18
-
-
45849132066
-
-
G. Allan, J. Davis, M. Dickins, I. Gardner, T. Jenkins, H. Jones, R. Webster, and H. Westgate Xenobiotica 38 2008 620
-
(2008)
Xenobiotica
, vol.38
, pp. 620
-
-
Allan, G.1
Davis, J.2
Dickins, M.3
Gardner, I.4
Jenkins, T.5
Jones, H.6
Webster, R.7
Westgate, H.8
-
19
-
-
84862821052
-
-
Rat cytosol incubations were conducted at 37 °C for a period of 45 min (protein 2 mg/mL) in a 96 well plate. To 20 μL of cytosol (BD, Gentest, 20 mg/mL), 170 μL of 100 mM phosphate buffer (pH 7.4) and 10 μL of substrate (20 μM) were added. The plate was vortex mixed and sample aliquots of 40 μL were taken at 0, 5, 15, 30, 45 min time points. The reaction was terminated followed by vortexing for 1 min and then centrifuged. 150 μL of supernatants were transferred to a new 96 deep well plate for LC/MS analysis. Aliquots(10 μL) were injected into the LCMS. Zoniporide was simultaneously run during the incubation and was used as (+) control. Human cytosol incubations were conducted in a similar manner to rat but using human cytosol (Celsis, OLA lot, 20 mg/ml). These assays can be run in the presence or absence of menadione, a specific aldehyde oxidase inhibitor
-
Rat cytosol incubations were conducted at 37 °C for a period of 45 min (protein 2 mg/mL) in a 96 well plate. To 20 μL of cytosol (BD, Gentest, 20 mg/mL), 170 μL of 100 mM phosphate buffer (pH 7.4) and 10 μL of substrate (20 μM) were added. The plate was vortex mixed and sample aliquots of 40 μL were taken at 0, 5, 15, 30, 45 min time points. The reaction was terminated followed by vortexing for 1 min and then centrifuged. 150 μL of supernatants were transferred to a new 96 deep well plate for LC/MS analysis. Aliquots(10 μL) were injected into the LCMS. Zoniporide was simultaneously run during the incubation and was used as (+) control. Human cytosol incubations were conducted in a similar manner to rat but using human cytosol (Celsis, OLA lot, 20 mg/ml). These assays can be run in the presence or absence of menadione, a specific aldehyde oxidase inhibitor.
-
-
-
-
20
-
-
34648830277
-
-
R.A. Torres, K.R. Korzekwa, D.R. McMasters, C.M. Fandozzi, and J.P. Jones J. Med. Chem. 50 2007 4642
-
(2007)
J. Med. Chem.
, vol.50
, pp. 4642
-
-
Torres, R.A.1
Korzekwa, K.R.2
McMasters, D.R.3
Fandozzi, C.M.4
Jones, J.P.5
-
21
-
-
84862782749
-
-
The calculations consisted of four steps. (1) create 3D structures of the substrates, (2) generate 3D structures of the products created by the addition of hydroxyl anion to each position on the substrate where the substituent was hydrogen, and could potentially be extracted by the sulfur atom of MoCo, (3) optimize structures by density functional theory at a B3LYP level with 6-31G basis sets on all constituent atoms, and finally (4) calculate differences between the energy of the products and the substrates plus the hydroxyl anion, which provides reaction energies. No transition state search was performed for the reactive intermediate of the modelled transformation, but was approximated from product stability as suggested by Hammond's postulate
-
The calculations consisted of four steps. (1) create 3D structures of the substrates, (2) generate 3D structures of the products created by the addition of hydroxyl anion to each position on the substrate where the substituent was hydrogen, and could potentially be extracted by the sulfur atom of MoCo, (3) optimize structures by density functional theory at a B3LYP level with 6-31G basis sets on all constituent atoms, and finally (4) calculate differences between the energy of the products and the substrates plus the hydroxyl anion, which provides reaction energies. No transition state search was performed for the reactive intermediate of the modelled transformation, but was approximated from product stability as suggested by Hammond's postulate.
-
-
-
|